Marek's disease virus (MDV) Meq oncoprotein in the pathogenesis of Marek's disease and the development of MDV vaccine strains
Marek's disease virus (MDV) Meq oncoprotein in the pathogenesis of Marek's disease and the development of MDV vaccine strains
批准号:
BB/G001197/1
负责人:
Martin Allday
金额:
$42.12万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2008
资助国家:
英国
项目状态:
已结题
起止时间:
2008 至 --
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Marek's disease (MD) is a common disease of chickens involving paralysis and commonly death from the growth of highly malignant T lymphomas (cancers of white blood cells). Unusual for a cancer, MD is caused by a transmissible agent, Marek's disease virus (MDV). MDV is very contagious and is a major threat to the poultry industry worldwide, but it can be controlled by vaccination. More than 5 billion vaccine doses a year are used in an attempt to control the disease. However, there is a continuous evolution of the virus towards greater virulence and consequently new vaccines are required. The mechanisms by which the virus gains virulence and produces tumours remain very poorly understood. Similarly, the factors that determine an effective vaccine strain remain unclear. With financial support from the BBSRC, we have been studying a protein called Meq that is made by MDV in the cancer cells. Our recent results have demonstrated unequivocally that this protein is absolutely essential for the induction of tumours by MDV (it is therefore known as an oncoprotein). Moreover it has been possible to identify specific protein:protein interactions involving Meq that are necessary for its function as an oncoprotein. We have made various defined mutations in the Meq-encoding gene that produce attenuated (non-pathogenic) MDV that we showed can be used as vaccines. This is a proposal to build on this work in order to determine the precise contribution that Meq makes to the development of Marek's disease in its various pathological manifestations / including malignant and paralytic forms / and to try and understand better what constitutes an effective vaccine strain of MDV.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
登录
查看更多内容
黏液层/细菌被膜双重渗透型抗菌聚多肽纳米载体用于肺部给药治疗慢性阻塞性肺病
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:虞桂平
-
依托单位:
Got2基因对浆细胞样树突状细胞功能的调控及其在系统性红斑狼疮疾病中的作用研究
-
批准号:82371801
-
项目类别:面上项目
-
资助金额:47.00万元
-
批准年份:2023
-
负责人:周海波
-
依托单位:
Erk1/2/CREB/BDNF通路在CSF1R相关性白质脑病致病机制中的作用研究
-
批准号:82371255
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:曹立
-
依托单位:
肠道菌群介导的脱氧胆酸激活S1PR2/NLRP3/IL-1β通路在炎症性肠病合并艰难梭菌感染中的致病机制研究
-
批准号:82372306
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:彭奕冰
-
依托单位:
噬菌体靶向肠道粪肠球菌提高帕金森病左旋多巴疗效的机制研究
-
批准号:82371251
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:肖勤
-
依托单位:
PET/MR多模态分子影像在阿尔茨海默病炎症机制中的研究
-
批准号:82372073
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:张淼
-
依托单位:
G蛋白偶联受体GPR110调控Lp-PLA2抑制非酒精性脂肪性肝炎的作用及机制研究
-
批准号:82370865
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:黄哲
-
依托单位:
牙周炎对腹主动脉瘤的作用和机制研究
-
批准号:82370953
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:朱亚琴
-
依托单位:
DJ-1与Calnexin互作调控线粒体—内质网联络区参与帕金森病病理机制的研究
-
批准号:82371414
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:黄沛
-
依托单位:
DACH1对糖尿病肾病足细胞脂质代谢的调控作用和机制研究
-
批准号:82370719
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:曹爱丽
-
依托单位: